Oppenheimer Comments On Unfounded Jarden Weakness

According to Oppenheimer, Jarden (NYSE: JAH) weaknesses are unfounded.

Oppenheimer said that it believes the recent weakness in the shares of JAH since reporting solid 1Q results in late April—in our view largely predicated on top-line fears—are unfounded. “Further, we would use this weakness as a buying opportunity ahead of our upcoming Oppenheimer Consumer Conference later this month, where management is expected to provide an upbeat business assessment, while valuation remains compelling.”

Jarden closed yesterday at $32.04.